NCT02108795

Brief Summary

The aim of the present study is to assess the effect of postoperative remifentanil infusion on the incidence of emergence agitation in preschool-aged children undergoing strabismus surgery with sevoflurane anaesthesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2014

Completed
1 day until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 9, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

July 16, 2015

Status Verified

July 1, 2015

Enrollment Period

2 years

First QC Date

March 31, 2014

Last Update Submit

July 14, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • the scale of emergence agitation

    A blinded observer record emergence agitation at just after laryngeal mask removal, 5 minutes after arrival in postanesthetic care unit, 10 minutes after arrival in postanesthetic care unit, 15 minutes after arrival in postanesthetic care unit, 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.

    up to 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.

Secondary Outcomes (1)

  • the effect of remifentanil on the emergence

    up to 30 minutes after the discharge form postanesthetic care unit

Study Arms (2)

remifentanil group

EXPERIMENTAL

Remifentanil 0.05 ug/kg/min is infused to the patients.

Drug: Remifentanil

control

PLACEBO COMPARATOR

Normal saline 0.2 ml/kg/hour is infused to the patients

Drug: Placebo

Interventions

Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)

Also known as: remifentanil (ultiva)
remifentanil group
control

Eligibility Criteria

Age3 Years - 7 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • American Society of Anesthesiologists physical status I and II
  • preschool-aged children undergoing strabismus surgery

You may not qualify if:

  • psychological disorders
  • emotional disorders
  • abnormal cognitive development
  • developmental delay
  • allergy to the drugs in our protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesiology and Pain Medicine, Yeungnam University hospital

Daegu, 705-035, South Korea

RECRUITING

MeSH Terms

Conditions

Delirium

Interventions

Remifentanil

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Sangjin Park, M.D.

    Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sangjin Park, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

March 31, 2014

First Posted

April 9, 2014

Study Start

April 1, 2014

Primary Completion

April 1, 2016

Study Completion

May 1, 2016

Last Updated

July 16, 2015

Record last verified: 2015-07

Locations